Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical ...
Please provide your email address to receive an email when new articles are posted on . A general practitioner-led program for genetic high cholesterol treatment was projected to be cost-effective vs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results